DOCSLIB.ORG

Shaping the Market: Gavi's Model for Bringing the Power of Vaccines To

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

#GaviSeth Shaping the market: Gavi’s model for bringing the power of vaccines to the world’s poorest children Seth Berkley MD National Vaccine Advisory Committee 2 February 2015, Washington DC www.gavi.org The challenge: Reducing delays in launching new vaccines in poor countries 2 #vaccineswork Gavi: an innovative public-private partnership Building on the comparative advantages of both public and private partners 3 #vaccineswork Gavi-supported vaccination programmes: an overview Refers to the first Gavi-supported introduction of each vaccine. Vaccine Investment Strategy: Gavi’s approach to prioritsing new vaccines Category VIS Criteria • Cholera Impact on child mortality Health Impact on overall mortality • Dengue impact • Hepatitis A Impact on overall morbidity • Hepatitis B (birth dose) Epidemic potential Global or regional public health priority • Hepatitis E Herd immunity Additional • Influenza* impact Availability of alternative interventions considerations • Meningococcal CYW Socio-economic inequity • Malaria Gender inequity • Rabies Disease of regional importance • Yellow Fever** Capacity and supplier base • DTP booster GAVI market shaping potential Implementation Ease of supply chain integration • Enterovirus 71 feasibility • Mumps Ease of programmatic integration Vaccine efficacy and safety * Maternal vaccination Vaccine procurement cost Cost and value ** Additional mass campaigns In-country operational cost for money Procurement cost per event averted Gavi’s unusual development model Co-financing Market- shaping Donor base HOW THE CO-FINANCING POLICY WORKS Co-financing level (per dose) Source: Gavi 2015. 7 #vaccineswork Changing mindsets In the vaccine manufacturing industry CDC/ Judy Schmidt, CDC/ Amanda Mills Amanda CDC/ Schmidt,Judy CDC/ 8 #vaccineswork Changing mindsets In the vaccine manufacturing industry /2013/Adrian /2013/Adrian Brooks Gavi 9 #vaccineswork Evolution of pentavalent vaccine market Increasing volumes, growing number of suppliers, reducing prices Sources: UNICEF Supply Division 2015; country annual progress reports (requested doses). 10 #vaccineswork More secure vaccine supply 2001: 5 suppliers from 5 countries of production Belgium 1 France 1 Switzerland 1 Republic of Korea 1 Senegal 1 2001 Source: UNICEF Supply Division More secure vaccine supply 2001:2014: 516 suppliers manufacturers* from 5 countriesfrom 11 countries of production of production United Kingdom Netherlands 1 Russian Belgium 1 Federation 1 France 1 Bulgaria Germany Republic United States 2** Italy of Korea 12 China 1 Senegal 1 India 4 Singapore * Includes 14 Gavi suppliers and 2 manufacturers of Brazil 1 prequalified Gavi vaccines. Indonesia 1 ** One US manufacturer also produces in the Netherlands. Note: Country of production represents country of national regulatory agency responsible for vaccine lot release. 2014 Source: UNICEF Supply Division and WHO list of pre-qualified vaccines, 2014 China: from implementing country to Gavi donor 2002 2003 2004 Catalytic 2005 Gavi support 2006 2007 2008 2009 2010 Self-financing 2011 vaccines 2012 2013 2014 Supplier of Gavi- 2015 funded vaccines Gavi donor Advance market commitment (AMC) Accelerating the manufacture and delivery of vaccines Lewis Sala /2012/ Gavi , Loke Atul /2007/ Gavi Donors commit funds Manufacturers get Developing countries , for new vaccines that incentive to invest in R&D and Gavi pay long-term, meet stringent criteria – legally committing to lower price for the D.Rowe and are requested by supply vaccines at lower vaccines /2014/ developing countries, at prices in the long term Gavi pre-agreed price left to left right): from ( 14 #vaccineswork IFFIm frontloading Long-term donor pledges are converted into immediately available funding for immunisation Source: World Bank, 2015 15 #vaccineswork Advanced purchase commitment for Ebola • Gavi commits towards future procurement with prepayment • Merck commits to: • EUAL dossier acceptance by December 31 2015 • Make available 300,000 investigational doses by May 2016 • Submit for licensure by December 2017 16 #vaccineswork After years of progress, measles control efforts stagnating and elimination off-track MCV1 coverage stagnant for …and measles outbreaks resurgent in both past 5 years… developed and developing world Coverage with first dose of measles vaccine, % Reported measles cases July-November 2015 US: big outbreak - China: ~ first measles death 40,000 cases in 12 years, July ‘15 Jan-Sept ‘15 Launch of Global Vaccine Action Plan 90 85 80 75 DR Congo: ~ 70 20,000 cases 65 Jan-Sept ‘15 60 55 Australia: 50 Number of cases outbreak Aug-Sept ‘15 1999 2004 2009 2014 (51 countries or 26%) 0 (39 countries or 20%) 1 - 9 Global Gavi 73 (42 countries or 22%) 10 - 99 (20 countries or 10%) 100 - 999 (9 countries or 5%) ≥1000 (33 countries or 17%) No data reported to WHO HQ Not applicable Source: WHO/UNICEF Estimates of National Immunization Coverage 2014 revision, July 2015; WHO measles surveillance data as of 13 January 2016 17 #vaccineswork Gavi supporing the countries most at risk from infectious diseases Gavi supports the poorest countries, >300 infectious home to 60% of the world’s children diseases exist… …<30 currently vaccine preventable 18 #vaccineswork Powerful impact: meningitis A vaccine 450 million PEOPLE THREATENED MORE THAN 215 million PEOPLE VACCINATED SINCE 2010 IMPACT: Number450 millionof meningitis Apeople cases: live in Africa’sin “meningitis2008 in 2014 belt” across 26 countries Niger 842 0 Burkina Faso 156 0 Mali 16 0 Global health security: Gavi’s growing role in outbreak preparedness and response Yellow fever Measles outbreak Meningitis vaccine vaccine stockpile response stockpiles Oral cholera Ebola vaccine vaccine stockpile stockpile Four key enablers of vaccine development ENABLING VACCINE DEVELOPMENT Recognise the lack of market potential Build laboratory & outbreak investigation capabilities in countries Create repositories of potential agents & better catalogue their immunologic properties Develop vaccine vector platforms 21 #vaccineswork Vaccines reduce antibiotic resistance Incidence of antibiotic-resistant invasive pneumococcal disease in children < 2 years, South Africa (cases per 100,000 person-years) Source: A von Gottberg et al, for GERMS-SA. Publication submitted April 2014. Accelerating impact 2016–2020 Sources: Gavi strategic demand forecasts 9 and 10, Investing together for a healthy future: the 2016–2020 investment opportunity. THANK YOU www.gavi.org .
Recommended publications
  • Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine- Associated Paralytic Poliomyelitis — Beijing, China, 2014–2016

    Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine- Associated Paralytic Poliomyelitis — Beijing, China, 2014–2016

    Morbidity and Mortality Weekly Report Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine- Associated Paralytic Poliomyelitis — Beijing, China, 2014–2016 Dan Zhao, MD1; Rui Ma, MD1; Tao Zhou, MD1; Fan Yang, MD1; Jin Wu, MD2; Hao Sun3; Fang Liu, MD4; Li Lu, MD1; Xiaomei Li1; Shuyan Zuo, MD5; Wei Yao6; JianYin6 When included in a sequential polio vaccination schedule, the risk for VAPP associated with subsequent OPV doses. inactivated polio vaccine (IPV) reduces the risk for vaccine- Countries that have previously introduced at least 1 IPV dose associated paralytic poliomyelitis (VAPP), a rare adverse event before vaccination with OPV have rapidly eliminated VAPP associated with receipt of oral poliovirus vaccine (OPV). (1). IPV has been available in China’s private sector since During January 2014, the World Health Organization (WHO) 2009. After completion of immunogenicity studies (3–5), recommended introduction of at least 1 IPV dose into routine Beijing introduced IPV into the public sector EPI program in immunization schedules in OPV-using countries (1). The December 2014 as part of a sequential schedule that included Polio Eradication and Endgame Strategic Plan 2013–2018 1 dose of IPV at age 2 months, followed by 3 doses of trivalent recommended completion of IPV introduction in 2015 and OPV at ages 3, 4, and 48 months. After the global synchronized globally synchronized withdrawal of OPV type 2 in 2016 (2). withdrawal of all Sabin type 2 vaccines in April 2016, trivalent Introduction of 1 dose of IPV into Beijing’s Expanded Program OPV was replaced with bivalent OPV, which contains types 1 on Immunization (EPI) on December 5, 2014 represented and 3 oral polio vaccine viruses.
  • Valuing the Cost of Improving Chilean Primary Vaccination: a Cost Minimization Analysis of a Hexavalent Vaccine

    Valuing the Cost of Improving Chilean Primary Vaccination: a Cost Minimization Analysis of a Hexavalent Vaccine

    Olivera et al. BMC Health Services Research (2020) 20:295 https://doi.org/10.1186/s12913-020-05115-7 RESEARCH ARTICLE Open Access Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine Ignacio Olivera1, Carlos Grau1, Hugo Dibarboure2, Juan Pablo Torres3, Gustavo Mieres1, Luis Lazarov1, Fabián P. Alvarez4 and Juan Guillermo López Yescas5* Abstract Background: The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio ‘end-game’ strategy. Methods: We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26). Results: The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme.
  • Gavi's Vaccine Investment Strategy

    Gavi's Vaccine Investment Strategy

    Gavi’s Vaccine Investment Strategy Deepali Patel THIRD WHO CONSULTATION ON GLOBAL ACTION PLAN FOR INFLUENZA VACCINES (GAP III) Geneva, Switzerland, 15-16 November 2016 www.gavi.org Vaccine Investment Strategy (VIS) Evidence-based approach to identifying new vaccine priorities for Gavi support Strategic investment Conducted every 5 years decision-making (rather than first-come- first-serve) Transparent methodology Consultations and Predictability of Gavi independent expert advice programmes for long- term planning by Analytical review of governments, industry evidence and modelling and donors 2 VIS is aligned with Gavi’s strategic cycle and replenishment 2011-2015 Strategic 2016-2020 Strategic 2021-2025 period period 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 RTS,S pilot funding decision VIS #1 VIS #2 VIS #3 MenA, YF mass campaigns, JE, HPV Cholera stockpile, Mid 2017 : vaccine ‘long list’ Rubella, Rabies/cholera studies, Oct 2017 : methodology Typhoid Malaria – deferred Jun 2018 : vaccine shortlist conjugate Dec 2018 : investment decisions 3 VIS process Develop Collect data Develop in-depth methodology and Apply decision investment decision framework for cases for framework with comparative shortlisted evaluation analysis vaccines criteria Phase I Narrow long list Phase II Recommend for Identify long list to higher priority Gavi Board of vaccines vaccines approval of selected vaccines Stakeholder consultations and independent expert review 4 Evaluation criteria (VIS #2 – 2013) Additional Health Implementation
  • Vaccination Certificate Information Version: 21 July 2021

    Vaccination Certificate Information Version: 21 July 2021

    معلومات عن شهادة التطعيم، بالعربية 中文疫苗接种凭证信息 Informations sur le certificat de vaccination en FRANÇAIS Информация о сертификате вакцинации на РУССКОМ ЯЗЫКЕ Información sobre el Certificado de Vacunación en ESPAÑOL UN SYSTEM-WIDE COVID-19 VACCINATION PROGRAMME VACCINATION CERTIFICATE INFORMATION VERSION: 21 JULY 2021 ABOUT THE UN SYSTEM-WIDE COVID-19 VACCINATION PROGRAMME The UN is committed to ensuring the protection of its personnel. Tasked by the Secretary-General, the Department of Operational Support (DOS) is leading a coordinated, UN-system-wide effort to ensure the availability of vaccine to UN personnel, their dependents and implementing partners. The roll-out of the UN System-wide COVID-19 Vaccination Programme (the “Programme”) for UN personnel will provide a significant boost to the ability of personnel to stay and deliver on the Organization's mandates, to support beneficiaries in the communities they serve, and to contribute to our on-going work to recover better together from the pandemic. Information about the Programme is available at: https://www.un.org/en/coronavirus/vaccination ABOUT THE VACCINATION CERTIFICATE Upon administration of the requisite vaccine dosage, a certificate of vaccination is generated through the Programme’s registration platform (the “Platform”). The certificate generated by the Platform uses a standardized format, similar to the one used by the WHO in its “International Certificate of Vaccination or Prophylaxis” (Yellow) vaccination booklet. Note: This certificate may not dispense with travel restrictions put in place by the country(ies) of destination. As the nature of the pandemic continues to rapidly evolve, it is highly advisable to check the latest travel regulations.
  • Global Dynamics of a Vaccination Model for Infectious Diseases with Asymptomatic Carriers

    Global Dynamics of a Vaccination Model for Infectious Diseases with Asymptomatic Carriers

    MATHEMATICAL BIOSCIENCES doi:10.3934/mbe.2016019 AND ENGINEERING Volume 13, Number 4, August 2016 pp. 813{840 GLOBAL DYNAMICS OF A VACCINATION MODEL FOR INFECTIOUS DISEASES WITH ASYMPTOMATIC CARRIERS Martin Luther Mann Manyombe1;2 and Joseph Mbang1;2 Department of Mathematics, Faculty of Science University of Yaounde 1, P.O. Box 812 Yaounde, Cameroon 1;2;3; Jean Lubuma and Berge Tsanou ∗ Department of Mathematics and Applied Mathematics University of Pretoria, Pretoria 0002, South Africa (Communicated by Abba Gumel) Abstract. In this paper, an epidemic model is investigated for infectious dis- eases that can be transmitted through both the infectious individuals and the asymptomatic carriers (i.e., infected individuals who are contagious but do not show any disease symptoms). We propose a dose-structured vaccination model with multiple transmission pathways. Based on the range of the explic- itly computed basic reproduction number, we prove the global stability of the disease-free when this threshold number is less or equal to the unity. Moreover, whenever it is greater than one, the existence of the unique endemic equilibrium is shown and its global stability is established for the case where the changes of displaying the disease symptoms are independent of the vulnerable classes. Further, the model is shown to exhibit a transcritical bifurcation with the unit basic reproduction number being the bifurcation parameter. The impacts of the asymptomatic carriers and the effectiveness of vaccination on the disease transmission are discussed through through the local and the global sensitivity analyses of the basic reproduction number. Finally, a case study of hepatitis B virus disease (HBV) is considered, with the numerical simulations presented to support the analytical results.
  • Yellow Fever 2016

    Yellow Fever 2016

    Resident / Humanitarian Coordinator Report on the use of CERF funds RESIDENT / HUMANITARIAN COORDINATOR REPORT ON THE USE OF CERF FUNDS ANGOLA RAPID RESPONSE YELLOW FEVER 2016 RESIDENT/HUMANITARIAN COORDINATOR Pier Paolo Balladelli REPORTING PROCESS AND CONSULTATION SUMMARY a. Please indicate when the After Action Review (AAR) was conducted and who participated. Review agreed on 02/09/2016 and 07/09/2016. b. Please confirm that the Resident Coordinator and/or Humanitarian Coordinator (RC/HC) Report was discussed in the Humanitarian and/or UN Country Team and by cluster/sector coordinators as outlined in the guidelines. YES NO c. Was the final version of the RC/HC Report shared for review with in-country stakeholders as recommended in the guidelines (i.e. the CERF recipient agencies and their implementing partners, cluster/sector coordinators and members and relevant government counterparts)? YES NO Final version shared with UNICEF and UNDP, although this initiative was mainly implemented by WHO 2 I. HUMANITARIAN CONTEXT TABLE 1: EMERGENCY ALLOCATION OVERVIEW (US$) Total amount required for the humanitarian response: Source Amount CERF 3,000,000 Breakdown of total response COUNTRY-BASED POOL FUND (if applicable) 4,508,559 funding received by source OTHER (bilateral/multilateral) TOTAL 10,473,618 *The total amount does not match because this was considered an underfunded emergency. TABLE 2: CERF EMERGENCY FUNDING BY ALLOCATION AND PROJECT (US$) Allocation 1 – date of official submission: 06/04/2016- 05/10/2016 Agency Project code Cluster/Sector
  • The Hepatitis B Vaccine Is the Most Widely Used Vaccine in the World, with Over 1 Billion Doses Given

    The Hepatitis B Vaccine Is the Most Widely Used Vaccine in the World, with Over 1 Billion Doses Given

    Hepatitis B Vaccine Protect Yourself and Those You Love What is Hepatitis B? Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV), which attacks liver cells and can lead to liver failure, cirrhosis (scarring), or liver cancer later in life. The virus is transmitted through direct contact with infected blood and bodily fluids, and from an infected woman to her newborn at birth. Is there a safe vaccine for hepatitis B? YES! The good news is that there is a safe and effective vaccine for hepatitis B. The vaccine is a series, typically given as three shots over a six-month period that will provide a lifetime of protection. You cannot get hepatitis B from the vaccine – there is no human blood or live virus in the vaccine. The hepatitis B vaccine is the most widely used vaccine in the world, with over 1 billion doses given. The hepatitis B vaccine is the first "anti-cancer" vaccine because it can help prevent liver cancer! Who should be vaccinated against hepatitis B? The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) recommend the hepatitis B vaccine for all newborns and children up to 18 years of age, and all high-risk adults. All infants should receive the first dose of the vaccine in the delivery room or in the first 24 hours of life, preferably within 12 hours. (CDC recommends the first dose within 12 hours vs. the WHO recommendation of 24 hours.) The HBV vaccine is recommended to anyone who is at high risk of infection.
  • Hanna Nohynek @Hnohynek

    Hanna Nohynek @Hnohynek

    Biosketch Hanna Nohynek @hnohynek Hanna Nohynek is Chief Physician and Deputy Head of the Infectious Diseases Control and Vaccines Unit of the Department of Health Security at the Finnish Institute for Health and Welfare. She serves as secretary of the Finnish NITAG (KRAR), and leads the subgroup on Strategic development of the influenza vaccination programme and the subgroup on the SARS-CoV-2 vaccination strategy. She practices clinical medicine at a travel health clinic in Aava, Helsinki. She was instrumental in designing the first THL (KTL) health advisory for refugees and asylum seekers in Finland, studying the narcolepsy signal post pandemic vaccination, designing the introduction of the HPV vaccine to the national immunization programme, and the introduction of the live attenuated influenza vaccine for children. Her present research interests are register-based vaccine impact studies, evidence based policy/decision making, vaccine safety, hesitancy, SARS-CoV-2, RSV, influenza and pneumococcus. She coordinates the work packages on field studies and communication for IMI DRIVE on brand specific influenza vaccine effectiveness (www.drive-eu.org). She has authored more than 130 original articles (including the first scientific report on the association between pandemic influenza vaccination and narcolepsy), and she teaches, giving over 30 invited lectures annually and guiding elective, graduate and PhD students (presently Raija Auvinen and Idil Hussein). She belongs to the external faculty of the University of Tampere MSc course on Global Health. She has served on expert committees evaluating HBV, PCV and rota virus vaccines in Finland, and as an advisor to the EU, IMI, IVI, WHO, GAVI, SIDA/SRC, and the Finnish MOFA.
  • UNEP Mercury Treaty Protects Access to Thiomersal-Containing Vaccines

    UNEP Mercury Treaty Protects Access to Thiomersal-Containing Vaccines

    UNEP mercury treaty protects access to thiomersal-containing vaccines United Nations Environment Program has developed a treaty on mercury in an effort to protect human health and the environment by limiting mercury releases. In the course of the negotiations, a proposal was made to restrict vaccines that contain the preservative thiomersal under a section of the treaty that prohibits trade of mercury-added products. The implications of restricting thiomersal, an ethyl mercury-containing preservative, would be significant. According to SAGE, “Thiomersal-containing vaccines [are] safe, essential, and irreplaceable components of immunization programs, especially in developing countries, and…removal of these products would disproportionately jeopardize the health and lives of the most disadvantaged children worldwide.” The treaty annex that describes prohibited products specifically excludes “vaccines containing thiomersal as preservatives” under a short list of products the authors intended to emphasize were to be protected. Protecting access to vaccines came as the result of a strong partnership between WHO, UNICEF, GAVI, and civil society advocates and experts around the world to educate country delegates, who predominantly came from ministries of environment. This was also a wonderful partnership with animal health experts, who similarly rely on thiomersal for veterinary vaccines. By facilitating communication between ministries of health and ministries of environment, strong statements are made by delegates about the essential role of thiomersal-containing vaccines in protecting human health. PATH will be collecting and disseminating additional information about how the community came together around this issue and lessons learned in the coming months. .
  • (DTP-Hep B-Hib) Vaccine Into the EPI Programme

    (DTP-Hep B-Hib) Vaccine Into the EPI Programme

    EPIDEMIOLOGICAL UNIT Department of Health Services Ministry of Health Care and Nutrition 231, de Saram Place, Colombo 01000, Sri Lanka Telephone: (+94-11-) 2681548, 2695112, Fax: (+94-11-) 2696583, E-mail: [email protected], [email protected] My No: EPI/81/VII/2007 22nd October 2007 Provincial /Regional Directors of Health Services, Directors of Teaching Hospitals/Specialized Campaigns, M. SS /D.M.OO of Provincial /Base Hospitals, Heads of Decentralized Units and, Medical Officers of Health Introduction of combined pentavalent (DTP-Hep B- Hib) Vaccine into the EPI A decision has been taken to introduce Hib (Haemophilus Influenzae B) vaccine into the EPI programme in Sri Lanka from year 2008. This decision is based on the recommendation by the National Advisory Committee on Communicable Diseases. The Hib vaccine will be in the form of a combined pentavalent (DTP-HepB-Hib) vaccine, which would include DTP and Hep B and therefore would replace both DTP and Hepatitis B in the present schedule. Background The bacterium, Haemophilus influenzae type B (Hib), is an important cause of infections in infants and young children; severe disease in adults due to Hib is uncommon. Where it has been studied carefully, Hib is the leading cause of acute bacterial meningitis in infants and children less than five years old, accounting for one-third to one-half of all cases of bacterial meningitis in this age group. Bacterial meningitis is fatal unless treated immediately with antibiotics. Even with proper treatment 3-25% of affected children may die. Permanent disability with sequelae that include deafness, learning disabilities, and difficulties in movement is not uncommon among those who survive the infection.
  • Pentavalent and Hexavalent Vaccines

    Pentavalent and Hexavalent Vaccines

    Pentavalent and Hexavalent Vaccines Cold Chain Equipment Database ID 3_7 Year 2004 The freeze indicator is used to warn of freezing and is packed with vaccines that are sensitive to freezing temperatures: DTP, TT, DT, Td (freezing point of -6.5°C), hepatitis B (-0.5°C), liquid Hib and their combinations (DTP-HepB, and DTP-HepB+Hib vaccines) and JE. Every refrigerator storing vaccines should have a freeze indicator (Freeze Watch™). It is strongly recommended that one freeze indicator be placed in each cold box during vaccine transport and distribution. This is critical in places subject to low temperatures. Immunization in practice: a practical resource guide for Health workers – 2004 update_____Module 3: The cold chain WHO/IVB/04.06 Page 13 Vaccine Handling Database ID 81_1 Year 2006 The recommended conditions for storing vaccines used in immunization programmes are shown in Appendix 81_1. This diagram also indicates the maximum times and temperatures in each case. At the higher levels of the cold chain, i.e., at national (primary), and regional or province level, OPV must be kept frozen between - 15oC and -25oC. Freeze-dried vaccines (i.e., BCG, measles, MMR and yellow fever) may also be kept frozen at -15oC to -25oC if cold chain space permits, but this is neither essential nor recommended. At other levels of the cold chain (intermediate vaccine stores and health facilities), these vaccines should be stored between +2oC and +8oC. All other vaccines should be stored at between +2oC and +8oC at all levels of the cold chain. Liquid formulations of vaccines containing diphtheria, pertussis, tetanus, hepatitis B, Haemophilus influenzae type b, IPV and their combinations should not be frozen.
  • Vaccine Hesitancy

    Vaccine Hesitancy

    WHY CHILDREN WORKSHOP ON IMMUNIZATIONS ARE NOT VACCINATED? VACCINE HESITANCY José Esparza MD, PhD - Adjunct Professor, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA - Robert Koch Fellow, Robert Koch Institute, Berlin, Germany - Senior Advisor, Global Virus Network, Baltimore, MD, USA. Formerly: - Bill & Melinda Gates Foundation, Seattle, WA, USA - World Health Organization, Geneva, Switzerland The value of vaccination “The impact of vaccination on the health of the world’s people is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” Stanley Plotkin (2013) VACCINES VAILABLE TO PROTECT AGAINST MORE DISEASES (US) BASIC VACCINES RECOMMENDED BY WHO For all: BCG, hepatitis B, polio, DTP, Hib, Pneumococcal (conjugated), rotavirus, measles, rubella, HPV. For certain regions: Japanese encephalitis, yellow fever, tick-borne encephalitis. For some high-risk populations: typhoid, cholera, meningococcal, hepatitis A, rabies. For certain immunization programs: mumps, influenza Vaccines save millions of lives annually, worldwide WHAT THE WORLD HAS ACHIEVED: 40 YEARS OF INCREASING REACH OF BASIC VACCINES “Bill Gates Chart” 17 M GAVI 5.6 M 4.2 M Today (ca 2015): <5% of children in GAVI countries fully immunised with the 11 WHO- recommended vaccines Seth Berkley (GAVI) The goal: 50% of children in GAVI countries fully immunised by 2020 Seth Berkley (GAVI) The current world immunization efforts are achieving: • Equity between high and low-income countries • Bringing the power of vaccines to even the world’s poorest countries • Reducing morbidity and mortality in developing countries • Eliminating and eradicating disease WHY CHILDREN ARE NOT VACCINATED? •Vaccines are not available •Deficient health care systems •Poverty •Vaccine hesitancy (reticencia a la vacunacion) VACCINE HESITANCE: WHO DEFINITION “Vaccine hesitancy refers to delay in acceptance or refusal of vaccines despite availability of vaccination services.